Lumasiran sodium - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for lumasiran sodium and what is the scope of patent protection?
Lumasiran sodium
is the generic ingredient in one branded drug marketed by Alnylam Pharms Inc and is included in one NDA. There are fourteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.Lumasiran sodium has one hundred and sixty-seven patent family members in forty-two countries.
One supplier is listed for this compound.
Summary for lumasiran sodium
| International Patents: | 167 |
| US Patents: | 14 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| DailyMed Link: | lumasiran sodium at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for lumasiran sodium
Generic Entry Date for lumasiran sodium*:
Constraining patent/regulatory exclusivity:
Dosage:
SOLUTION;SUBCUTANEOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for lumasiran sodium
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alnylam Pharms Inc | OXLUMO | lumasiran sodium | SOLUTION;SUBCUTANEOUS | 214103-001 | Nov 23, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| Alnylam Pharms Inc | OXLUMO | lumasiran sodium | SOLUTION;SUBCUTANEOUS | 214103-001 | Nov 23, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| Alnylam Pharms Inc | OXLUMO | lumasiran sodium | SOLUTION;SUBCUTANEOUS | 214103-001 | Nov 23, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Alnylam Pharms Inc | OXLUMO | lumasiran sodium | SOLUTION;SUBCUTANEOUS | 214103-001 | Nov 23, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| Alnylam Pharms Inc | OXLUMO | lumasiran sodium | SOLUTION;SUBCUTANEOUS | 214103-001 | Nov 23, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| Alnylam Pharms Inc | OXLUMO | lumasiran sodium | SOLUTION;SUBCUTANEOUS | 214103-001 | Nov 23, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for lumasiran sodium
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Canada | 2958758 | AGENTS D'ARN DOUBLE BRIN MODIFIE (MODIFIED DOUBLE-STRANDED RNA AGENTS) | ⤷ Try a Trial |
| Canada | 2910760 | LIPIDES DE CIBLAGE (TARGETING LIPIDS) | ⤷ Try a Trial |
| Japan | 7337044 | ⤷ Try a Trial | |
| Canada | 2708173 | LIPIDES DE CIBLAGE (TARGETING LIPIDS) | ⤷ Try a Trial |
| Canada | 2930393 | CONJUGUES GLUCIDIQUES UTILISES EN TANT QU'AGENTS D'ADMINISTRATION POUR DES OLIGONUCLEOTIDES (CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES) | ⤷ Try a Trial |
| Jordan | 3558 | تركيبات وطرق لتثبيط التعبير الجيني عن HAO1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات)) (Compositions And Methods For Inhibition Of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) Gene Expression) | ⤷ Try a Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for lumasiran sodium
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 3581654 | 301132 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: LUMASIRAN; REGISTRATION NO/DATE: EU/1/20/1496 20201123 |
| 3581654 | 2021C/534 | Belgium | ⤷ Try a Trial | PRODUCT NAME: LUMASIRAN; AUTHORISATION NUMBER AND DATE: EU1/20/1496 20201123 |
| 3581654 | 21C1044 | France | ⤷ Try a Trial | PRODUCT NAME: LUMASIRAN; REGISTRATION NO/DATE: EU/1/20/1496 20201123 |
| 3581654 | CA 2021 00038 | Denmark | ⤷ Try a Trial | PRODUCT NAME: LUMASIRAN; REG. NO/DATE: EU/1/20/1496 20201123 |
| 3204015 | 22C1016 | France | ⤷ Try a Trial | PRODUCT NAME: LUMASIRAN, OPTIONNELLEMENT SOUS FORME DE SEL; NAT. REGISTRATION NO/DATE: EU/1/20/1496 20201123; FIRST REGISTRATION: - EU/1/20/1496 20201123 |
| 3581654 | LUC00218 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: LUMASIRAN; AUTHORISATION NUMBER AND DATE: EU/1/20/1496 20201123 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
